Drug intelligence / Profile preview

antithrombin III concentrate

Development stage
Approved
Lead developer
Grifols
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

**Antithrombin III concentrate** is a purified, sterile, lyophilized human plasma–derived protein product designed for intravenous replacement therapy in patients with hereditary antithrombin deficiency. Its principal mechanism is the direct replacement of missing or deficient antithrombin, a key endogenous inhibitor of thrombin and other activated coagulation factors (primarily factor Xa and thrombin), thereby restoring physiologic regulation of coagulation and preventing unwanted clot formation. The concentrate is indicated specifically for the treatment and prevention of thromboembolism, and for perioperative and peripartum prophylaxis in individuals with hereditary antithrombin deficiency[1][2][3][5]. Heparin strongly potentiates the activity of antithrombin, so the concentrate may be used alone or to augment heparin therapy[1][2][3][5].

Brand names
Thrombate IIIAntithrombin III NF
Other names
antithrombin III (human)antithrombin concentrateantithrombin III human
02

Targets

F10 (Factor Xa)F2 (Thrombin)FXIIa (Coagulation Factor XIIa)PLG (Plasminogen)Factor XIaCoagulation Factor IXa

Beyond the preview

Go deeper on antithrombin III concentrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on antithrombin III concentrate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call